Total assets have contracted 41.5% to $298.9M with cash of $99.3M against $48.5M of total debt (D/E 0.21), but the implied two-to-three-quarter runway at current burn rates warrants close monitoring.
Entrada Therapeutics, Inc. (TRDA) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 202.95M | 306.25M | 440.04M | 369.77M | 209.88M | 298.7M | 39.95M | 17.44M |
| Cash & Short-Term Investments | 193.01M | 295.7M | 420M | 351.97M | 188.71M | 291.06M | 39.05M | 16.84M |
| Cash Only | 112.24M | 90.39M | 101.21M | 67.6M | 45.16M | 291.06M | 39.05M | 16.84M |
| Short-Term Investments | 80.78M | 205.3M | 318.79M | 284.37M | 143.56M | 0 | 0 | 0 |
| Accounts Receivable | 838K | 2.58M | 3.68M | 5.88M | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 117.43 | 37 | 6.37 | 16.63 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 7.98M | 16.36M | 11.92M | 21.16M | 0 | 0 | 0 |
| Total Non-Current Assets | 63.93M | 71.13M | 86.28M | 99.42M | 42.18M | 7.13M | 3.58M | 801K |
| Property, Plant & Equipment | 60.51M | 67.76M | 82.05M | 92.68M | 33.02M | 6.26M | 3.04M | 801K |
| Fixed Asset Turnover | 0.06x | 0.38x | 2.57x | 1.39x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.42M | 3.36M | 4.23M | 6.74M | 9.16M | 872K | 541K | 0 |
| Total Assets | 266.88M | 377.38M | 526.32M | 469.19M | 252.06M | 305.83M | 43.53M | 18.24M |
| Asset Turnover | 0.01x | 0.07x | 0.40x | 0.27x | - | - | - | - |
| Asset Growth % | -128.1% | -28.3% | 12.18% | 86.15% | -17.58% | 602.63% | 138.66% | - |
| Total Current Liabilities | 25.86M | 24.45M | 39.48M | 158.8M | 21.97M | 6.72M | 3.36M | 1.92M |
| Accounts Payable | 4.87M | 2.29M | 4.26M | 3.28M | 5.99M | 706K | 1.6M | 710K |
| Days Payables Outstanding | 746.3 | 203.98 | - | - | - | - | 1.79K | 2.49K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 867K | 342K | 13.65M | 132.26M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 9.22M | 8.43M | 7.66M | 5.49M | 4.56M | 1.6M | 937K |
| Current Ratio | 7.85x | 12.53x | 11.15x | 2.33x | 9.55x | 44.46x | 11.89x | 9.08x |
| Quick Ratio | 7.85x | 12.53x | 11.15x | 2.33x | 9.55x | 44.46x | 11.89x | 9.08x |
| Cash Conversion Cycle | -628.87 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 42.69M | 46.79M | 58.16M | 68.04M | 17.53M | 396K | 81.66M | 31.84M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 179.05M | 46.79M | 51.65M | 60.32M | 17.53M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 396K | 81.66M | 31.84M |
| Total Liabilities | 68.56M | 71.25M | 97.64M | 226.83M | 39.5M | 7.12M | 85.02M | 33.76M |
| Total Debt | 47.31M | 50.93M | 59.21M | 68.23M | 25.94M | 0 | 0 | 0 |
| Net Debt | -64.92M | -39.46M | -42M | 628K | -19.22M | -291.06M | -39.05M | -16.84M |
| Debt / Equity | 0.24x | 0.17x | 0.14x | 0.28x | 0.12x | - | - | - |
| Debt / EBITDA | -0.28x | - | 1.17x | - | - | - | - | - |
| Net Debt / EBITDA | 0.38x | - | -0.83x | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -34.95x | - | - | - |
| Total Equity | 198.32M | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M | -41.49M | -15.52M |
| Equity Growth % | -143.96% | -28.59% | 76.88% | 14.02% | -28.84% | 819.98% | -167.37% | - |
| Book Value per Share | 4.68 | 7.40 | 10.99 | 7.33 | 6.79 | 9.57 | -1.33 | -14.81 |
| Total Shareholders' Equity | 198.32M | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M | -41.49M | -15.52M |
| Common Stock | 4K | 4K | 4K | 3K | 3K | 3K | 0 | 0 |
| Retained Earnings | -395.32M | -273.09M | -129.34M | -194.97M | -188.28M | -93.67M | -42.51M | -15.99M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -56K | 652K | -43K | 195K | -2.06M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying TRDA stock.
As of 2025, Entrada Therapeutics, Inc. (TRDA) had total assets of $377.4M including $306.3M in current assets.
Entrada Therapeutics, Inc. (TRDA) carries total debt of $50.9M, offset by $295.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Entrada Therapeutics, Inc. (TRDA) has total shareholders' equity (book value) of $306.1M ($7.40 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Entrada Therapeutics, Inc. (TRDA) reported a current ratio of 12.53x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash runway critically short
Metrics are mathematically derived from official filings.
Balance Sheet Erosion Accelerating Steadily
Entrada's total assets have contracted 41.5% from $510.8M in 2024Q1 to $298.9M in 2026Q2, driven by persistent cash burn and the collapse of deferred revenue from $157.9M to $173K, according to the company's quarterly balance sheets.
The trajectory is unambiguously negative. Total assets have declined in seven of the last nine quarters with no sign of stabilization, while accumulated deficit has widened from -$171.5M to -$355.6M — a $184M deterioration in retained earnings over the period. The fact that this erosion has continued despite operating expenses exceeding revenue by roughly 46:1 suggests the company is consuming capital at a rate that may not be sustainable beyond 2026.
Cash Buffer Thinning Against Heavy Burn
As reported in Entrada's financial statements, cash stood at $99.3M in 2026Q2 against a current ratio of 10.89, but with quarterly operating losses near $42M, the implied runway appears to be approximately two to three quarters absent new financing.
The current ratio of 10.89 superficially signals abundant liquidity, but this is misleading because current liabilities have collapsed to just $6.0M from $241.5M in 2024Q1 — primarily the elimination of deferred revenue. The more relevant metric is cash relative to operating burn: at roughly $40M+ per quarter of operating cash outflow (as evidenced by the $42.8M net loss in 2026Q2), $99.3M provides a buffer that may require management to seek capital markets access sooner rather than later.
Modest Debt Load Being Gradually Repaid
Based on Entrada's disclosed figures, total debt has declined from $66.4M in 2024Q1 to $48.5M in 2026Q2, with a debt-to-equity ratio of 0.21 that appears manageable relative to the $99.3M cash position.
The gradual ~27% reduction in debt over the period suggests either scheduled amortization or voluntary deleveraging, which is a modest positive. However, the D/E ratio of 0.21 overstates the balance sheet's strength because equity itself has deteriorated from $428.7M to $233.4M; on a cash-adjusted basis, net debt of -$50.8M means the company remains technically net cash positive, which preserves some strategic flexibility for refinancing if needed.
Asset Base Shrinking Without Goodwill Risk
Entrada's balance sheet carries zero goodwill across all ten periods, while net PPE has declined from $90.0M to $62.8M, per the company's quarterly filings, indicating a business whose asset base is concentrated in cash and working capital rather than intangibles.
The absence of goodwill is notable for a biotech and eliminates one common impairment risk that peers like ARWR or NTLA might carry. However, the steady $27M decline in PPE — with capex consistently below $1.1M against depreciation exceeding that in most quarters — signals the company is not reinvesting in its physical infrastructure. For a business still spending $35M+ quarterly on R&D, the fact that tangible assets are shrinking suggests the R&D spend may be primarily personnel- and partnership-driven rather than capital-intensive laboratory work.
Deferred Revenue Collapse Obscures True Health
The most underappreciated balance sheet distortion is deferred revenue plunging from $157.9M in 2024Q1 to $173K by 2026Q2, which masked the severity of the cash burn by artificially inflating total liabilities and equity in prior periods.
The $157.9M of deferred revenue in early 2024 represented previously collected cash that had not yet been recognized as revenue. As this obligation was liquidated — either through revenue recognition or refund — it simultaneously reduced total liabilities (improving the current ratio optics) and reduced equity through the associated revenue/expense recognition. This means the balance sheet's apparent improvement in leverage and liquidity ratios over the period is substantially a mechanical artifact of deferred revenue unwinding, not evidence of fundamental strengthening. Investors should treat the reported current ratio and D/E with significant skepticism given this distortion.